Colorectal CancerTAPNCT06370949
The Effectiveness of Bupivacaine and Bupivacaine+Dexmedetomidine Combination in Transversus Abdominis Plane* Block
An observational study of Colorectal Cancer and Colorectal Neoplasms, run by Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital at 1 site in Turkey (Türkiye).
Trial summary
Transversus abdominis plane (TAP) block is an anesthesia method that provides somatic analgesia to the anterior and lateral abdominal walls. Thus, TAP block is widely implemented in perioperative management of colorectal cancer patients. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Colorectal Cancer, Colorectal Neoplasms
- What is being tested?
- Bupivacain and bupivacain+dexmedetomidine
- How many people
- 84 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 May 2024to 1 May 2025
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The investigators will evaluate colorectal cancer patients from Ankara Dr. Abdurrahman Yurtaslan Oncology Train and Research Hospital who will undergo colorectal cancer surgery. The investigators will exclude patients who no longer want to participate at any part of the trial. A total of 84 patients' data will be collected.
Who may be able to join
- colorectal cancer diagnosis
- undergoing colorectal cancer surgery
Who cannot join
- allergic reaction to local anesthetics
- bleeding anomalies
- infection in TAP block area
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Turkey Dr.Abdurrahman Yurtaslan Ankara Oncology Train and Research Hospital
Ankara, Cankaya, 06110
About this study
Official title: Comparison of the Effectiveness of Bupivacaine and Bupivacaine+Dexmedetomidine Combination in Transversus Abdominis Plane* Block in Colorectal Cancer Surgery
Transversus abdominis plane (TAP) block is an anesthesia method that provides somatic analgesia to the anterior and lateral abdominal walls. Thus, TAP block is widely implemented in perioperative management of colorectal cancer patients.
Researchers aimed to evaluate the analgesic effectiveness and duration of effect of dexmedetomidine added to bupivacaine in the TAP block applied in colorectal cancer surgeries.
Read the detailed description
Transversus abdominis plane (TAP) block is an anesthesia method that provides somatic analgesia to the anterior and lateral abdominal walls. With the increasing use of ultrasound guidance during peripheral nerve blocks, trunk blocks such as the transversus abdominis plane (TAP) block are widely used for analgesia after abdominal surgery.
The advantages of TAP block include being less invasive than epidural analgesia, lower incidence of hypotension, and shorter hospital stay. Due to these advantages, TAP block has become a widely preferred method.
Researchers aimed to evaluate the analgesic effectiveness and duration of effect of dexmedetomidine added to bupivacaine in the TAP block applied in colorectal cancer surgeries. The study will be conducted in a tertiary oncology hospital in Turkey and 84 colorectal cancer patients will be included.
- Conditions
- Colorectal Cancer, Colorectal Neoplasms
- Being tested
- Bupivacain, bupivacain+dexmedetomidine
- Keywords
- colorectal cancer, colorectal cancer surgery, colorectal neoplasym, transversus abdominis plane, transversus abdominis plane block
- Medical subject headings
- Colorectal Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BupivacainDrug
Ultrasonography (USG) guided bilateralTAP block:20 ml %0,25 concentration bupivacain
bupivacain+dexmedetomidineDrug
Ultrasonography (USG) guided bilateral TAP block: 20 ml %0,25 concentration bupivacain+ 0.5 mcg/kg dexmedetomidine
| Study group | Role | What they receive |
|---|---|---|
| bupivacaine | Ultrasonography (USG) guided bilateral TAP block:20 ml %0,25 concentration bupivacain Receives: Drug: Bupivacain | |
| bupivacaine+dexmedetomidine | Ultrasonography (USG) guided bilateral TAP block: 20 ml %0,25 concentration bupivacain+ 0.5 mcg/kg dexmedetomidine Receives: Drug: bupivacain+dexmedetomidine |
What is being measured
The primary outcome is the main question the study is designed to answer.
Analgesic effectiveness of bupivacain and bupivacain+dexmedetomidine combination in colorectal cancer surgery
Numeric Rating Scales of two groups in postoperative period. The numeric rating scale (NRS) is a pain screening tool, commonly used to assess pain severity at that moment in time using a 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable"
Measured: postoperative day two
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Apr 2024
- Study start1 May 2024
- Primary completion5 Feb 2025
- Study completion1 May 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Colorectal CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 84 participants (actual)
Sponsor and investigators
- Lead sponsor
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Beyza Seker, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital
- Investigators
- Beyza Seker, MD, Principal investigator, Resident MD
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06370949
- Sponsor's protocol ID
- 2024-01/17
- Acronym
- TAP
- Status last verified
- Jun 2026
- First submitted
- 13 Apr 2024
- Last updated
- 2 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of the Effectiveness of Bupivacaine and Bupivacaine+Dexmedetomidine Combination in Transversus Abdominis Plane* Block in Colorectal Cancer Surgery
- ClinicalTrials.gov ID
- NCT06370949
- Acronym / sponsor ID
- TAP / 2024-01/17
- Conditions
- Colorectal Cancer, Colorectal Neoplasms
- Keywords
- colorectal cancer, colorectal cancer surgery, colorectal neoplasym, transversus abdominis plane, transversus abdominis plane block
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 84 participants (actual)
- Lead sponsor
- Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research HospitalUniversity, hospital or other
- Study start
- 1 May 2024 (actual)
- Primary completion
- 5 Feb 2025 (actual)
- Study completion
- 1 May 2025 (actual)
- First posted
- 17 Apr 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Transversus abdominis plane (TAP) block is an anesthesia method that provides somatic analgesia to the anterior and lateral abdominal walls. Thus, TAP block is widely implemented in perioperative management of colorectal cancer patients.
Researchers aimed to evaluate the analgesic effectiveness and duration of effect of dexmedetomidine added to bupivacaine in the TAP block applied in colorectal cancer surgeries.
Detailed description
Transversus abdominis plane (TAP) block is an anesthesia method that provides somatic analgesia to the anterior and lateral abdominal walls. With the increasing use of ultrasound guidance during peripheral nerve blocks, trunk blocks such as the transversus abdominis plane (TAP) block are widely used for analgesia after abdominal surgery.
The advantages of TAP block include being less invasive than epidural analgesia, lower incidence of hypotension, and shorter hospital stay. Due to these advantages, TAP block has become a widely preferred method.
Researchers aimed to evaluate the analgesic effectiveness and duration of effect of dexmedetomidine added to bupivacaine in the TAP block applied in colorectal cancer surgeries. The study will be conducted in a tertiary oncology hospital in Turkey and 84 colorectal cancer patients will be included.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| bupivacaine | – | Drug: BupivacainUltrasonography (USG) guided bilateral TAP block:20 ml %0,25 concentration bupivacain |
| bupivacaine+dexmedetomidine | – | Drug: bupivacain+dexmedetomidineUltrasonography (USG) guided bilateral TAP block: 20 ml %0,25 concentration bupivacain+ 0.5 mcg/kg dexmedetomidine |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The investigators will evaluate colorectal cancer patients from Ankara Dr. Abdurrahman Yurtaslan Oncology Train and Research Hospital who will undergo colorectal cancer surgery. The investigators will exclude patients who no longer want to participate at any part of the trial. A total of 84 patients' data will be collected.
Key inclusion criteria (2 listed)
- colorectal cancer diagnosis
- undergoing colorectal cancer surgery
Key exclusion criteria (3 listed)
- allergic reaction to local anesthetics
- bleeding anomalies
- infection in TAP block area
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BupivacainUltrasonography (USG) guided bilateralTAP block:20 ml %0,25 concentration bupivacain | Drug | bupivacaine |
| bupivacain+dexmedetomidineUltrasonography (USG) guided bilateral TAP block: 20 ml %0,25 concentration bupivacain+ 0.5 mcg/kg dexmedetomidine | Drug | bupivacaine+dexmedetomidine |
Primary outcome
Analgesic effectiveness of bupivacain and bupivacain+dexmedetomidine combination in colorectal cancer surgery
Time frame: postoperative day two
Numeric Rating Scales of two groups in postoperative period. The numeric rating scale (NRS) is a pain screening tool, commonly used to assess pain severity at that moment in time using a 0-10 scale, with zero meaning "no pain" and 10 meaning "the worst pain imaginable"
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jul 2026.
Related trials for Colorectal Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingObservational study
Pre- and On-treatment Multi-omics Profiling of Locally Advanced Rectal Cancer
Rectal Neoplasms
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
RecruitingPhase 2
Tislelizumab in People With Colorectal Cancer
Colorectal Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Beyza Seker, MD principal investigator
Resident MD
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Colorectal Cancer and Colorectal Neoplasms, run by Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Analgesic effectiveness of bupivacain and bupivacain+dexmedetomidine combination in colorectal cancer surgery (time frame: postoperative day two). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2026.